Multiple sclerosis patients have a diminished serologic response to vitamin D supplementation compared to healthy controls

Abstract

Background:

Vitamin D insufficiency is a risk factor for multiple sclerosis (MS), and patients do not always show the expected response to vitamin D supplementation.

Objective:

We aimed to determine if vitamin D supplementation leads to a similar increase in serum 25-hydroxyvitamin-D (25(OH)D) levels in patients with MS and healthy controls (HCs).

Methods:

Participants in this open-label study were female, white, aged 18–60 years, had 25(OH)D levels ⩽ 75 nmol/l at screening, and had relapsing–remitting MS (RRMS) or were HCs. Participants received 5000 IU/day of vitamin D₃ for 90 days. Utilizing generalized estimating equations we examined the relationship between the primary outcome (serum 25(OH)D level) and the primary (MS versus HC status) and secondary predictors.

Results:

For this study 27 MS patients and 30 HCs were enrolled. There was no significant difference in baseline 25(OH)D level or demographics except for higher body mass index (BMI) in the MS group (25.3 vs. 23.6 kg/m², p=0.035). In total, 24 MS subjects and 29 HCs completed the study. In a multivariate model accounting for BMI, medication adherence, and oral contraceptive use, MS patients had a 16.7 nmol/l (95%CI: 4.2, 29.2, p=0.008) lower increase in 25(OH)D levels compared with HCs.

Conclusions:

Patients with MS had a lower increase in 25(OH)D levels with supplementation, even after accounting for putative confounders.

Keywords

Multiple sclerosis vitamin D supplementation pharmacokinetics nutrition

Get full access to this article

View all access options for this article.

References

Munger

Levin

Hollis

. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296: 2832–2838.

Di Rosa

Malaguarnera

Nicoletti

. Vitamin D3: A helpful immuno-modulator. Immunology 2011; 134: 123–139.

Joshi

Pantalena

L-C

Liu

. 1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A. Mol Cell Biol 2011; 31: 3653–3669.

Lemire

Archer

DC.

1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis.J Clin Invest 1991; 87: 1103–1107.

Mowry

Krupp

Milazzo

. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010; 67: 618–624.

Simpson

Taylor

Blizzard

. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010; 68: 193–203.

Hiremath

Cettomai

Baynes

. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009; 15: 735–740.

Anon. Genome-wide association study identifies new multiple sclerosis susceptibility loci on chromosomes 12 and 20. Nat Genet 2009; 41: 824–828.

Sawcer

Hellenthal

Pirinen

. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

10.

Ramagopalan

S V

Dyment

Cader

. Rare variants in the CYP27B1 gene are associated with multiple sclerosis. Ann Neurol 2011; 70: 881–886.

11.

Tajouri

Ovcaric

Curtain

. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet 2005; 19: 25–38.

12.

Dörr

Ohlraun

Skarabis

. Efficacy of vitamin D supplementation in multiple sclerosis (EVIDIMS Trial): Study protocol for a randomized controlled trial. Trials 2012; 13: 15.

13.

Smolders

Hupperts

Barkhof

. Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci 2011; 311: 44–49.

14.

Bhargava

Cassard

Steele

. The Vitamin D to Ameliorate Multiple Sclerosis (VIDAMS) trial: Study design for a multicenter, randomized, double-blind controlled trial of vitamin D in multiple sclerosis. Contemp Clin Trials 2014; 39: 288–293.

15.

Anon. Climate Prediction Center – Stratosphere: UV Index: Annual Time Series. Available at: http://www.cpc.ncep.noaa.gov/products/stratosphere/uv_index/uv_annual.shtml (accessed 31 October 2014).

16.

Polman

Reingold

Edan

. Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005; 58: 840–846.

17.

Kurtzke

JF.

Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452.

18.

Block

Woods

Potosky

. Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 1990; 43: 1327–1335.

19.

Block

Gillespie

Rosenbaum

. A rapid food screener to assess fat and fruit and vegetable intake. Am J Prev Med 2000; 18: 284–288.

20.

Cummings

Block

McHenry

. Evaluation of two food frequency methods of measuring dietary calcium intake. Am J Epidemiol 1987; 126: 796–802.

21.

Chan

Jaceldo-Siegl

Fraser

GE.

Serum 25-hydroxyvitamin D status of vegetarians, partial vegetarians, and nonvegetarians: The Adventist Health Study-2. Am J Clin Nutr 2009; 89: 1686S–1692S.

22.

Heaney

Davies

Chen

. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204–210.

23.

Stewart

Simpson

van der Mei

. Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology 2012; 79: 254–260.

24.

Bhargava

Sotirchos

Eckstein

. High-dose vitamin D supplementation reduces IL-17-producing CD4+ T-cells and effector-memory CD4+ T-cells in multiple sclerosis patients (S38.001) Neurology 2015; 84(14_Supplement): S38.001.

25.

el-Maghraby

TAF

Shalaby

Al-Tawdy

. Gastric motility dysfunction in patients with multiple sclerosis assessed by gastric emptying scintigraphy. Can J Gastroenterol 2005; 19: 141–145.

26.

Wong

Enomoto

Leopold

. Intestinal absorption of dietary fat in patients with multiple sclerosis. Metab Pediatr Syst Ophthalmol 1993; 16: 39–42.

27.

Dawson

Karpen

SJ.

Intestinal transport and metabolism of bile acids. J Lipid Res 2015; 56: 1085–1099.

28.

Hanly

Ryan

Snelling

. Association between bile acid turnover and osteoporosis in postmenopausal women. Nucl Med Commun 2013; 34: 597–600.

29.

Ban

Caillier

Mero

I-L

. No evidence of association between mutant alleles of the CYP27B1 gene and multiple sclerosis. Ann Neurol 2013; 73: 430–432.

30.

Bryant

Koenigsfeld

Lehman

. A retrospective evaluation of response to vitamin D supplementation in obese versus nonobese patients. J Pharm Pract 2014; Epub ahead of print. Available at: http://www.ncbi.nlm.nih.gov/pubmed/25124377 (accessed 19 October 2014).

31.

Singh

Bonham

. A predictive equation to guide vitamin D replacement dose in patients. J Am Board Fam Med 27: 495–509.

32.

Tepper

Shahar

Geva

. Predictors of serum 25(Oh)D increase following bimonthly supplementation with 100,000IU vitamin D in healthy, men aged 25–65 years. J Steroid Biochem Mol Biol 2014; 144: 163–166.

33.

Harris

Dawson-Hughes

The association of oral contraceptive use with plasma 25-hydroxyvitamin D levels. J Am Coll Nutr 1998; 17: 282–284.

34.

Møller

Streym

S við

Jensen

. Increased plasma concentrations of vitamin D metabolites and vitamin D binding protein in women using hormonal contraceptives: A cross-sectional study. Nutrients 2013; 5: 3470–3480.

35.

Nylén

Björkhem-Bergman

Ekström

. Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: Effects of a genetic polymorphism and oral contraceptives. Basic Clin Pharmacol Toxicol 2014; 115: 366–371.